ClinicalTrials.gg
CompletedNCT05248880Updated Feb 18, 2026Results posted

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

A Phase 3 interventional study of AGN-151586 and Placebo in Glabellar Lines, sponsored by AbbVie. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in toxin-naïve participants with moderate to severe GL.

This is a 12 week study in which eligible subjects will be enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants are randomly assigned to receive AGN-151586 or placebo. There is 1 in a 4 chance that participants will receive placebo. Around 300 adult participants with moderate to severe GL will be enrolled in the study in approximately 15 sites.

Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive an open-label treatment of AGN-151586 during the study.

Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

02

Conditions studied

  • Glabellar Lines

Keywords

  • Glabellar Lines
  • AGN-151586
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to accurately assess their facial lines without the use of eyeglasses (contact lens use is acceptable).
  • Participant must have moderate or severe Glabellar Lines at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at Screening and Baseline Day 1 visit.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease.
  • Participants must not have a history of any use of botulinum neurotoxin of any serotype for any indication (including any botulinum neurotoxin product).
  • Presence or history of any medical condition that may place the participant at increased risk following exposure to AGN-151586 or interfere with the study evaluation, including:

    • Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
    • History of facial nerve palsy
    • Infection or dermatological condition at the treatment injection sites
    • Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart
    • Any eyebrow or eyelid ptosis at screening or Baseline Day 1 visit as determined by the investigator
  • History of known immunization to any botulinum neurotoxin serotype.
  • Tattoos, jewelry, or clothing which obscure the glabellar area and cannot be removed.
  • Anticipated need for surgery or overnight hospitalization during the study.
  • History of surgical procedures on forehead and/or periorbital areas or affecting these areas including any lifting procedure (e.g., rhinoplasty, facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).
  • History of periorbital, mid-facial, or upper-facial treatment with semi permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.
  • Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Female subject who is pregnant or breastfeeding, and is considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study drug or until the end of study, whichever is longer.
  • Participant who has been treated with any investigational drug within 30 days of the drug prior to the first dose of study drug or is currently enrolled in another clinical study or was previously enrolled in this study.
  • Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study drug).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    AGN-151586

    Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.

    Drug: AGN-151586

  • Experimental
    Placebo

    Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.

    Drug: AGN-151586 · Drug: Placebo

Interventions

  • Intramuscular Injection

  • DrugPlacebo

    Intramuscular Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]

    \[Primary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind period)

  2. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

    \[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind period)

  3. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

    \[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

  4. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: From time of informed consent to end of study; median time on follow-up was 85 days for all groups.

Secondary outcomes

  1. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Participant Assessments of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

    \[Secondary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  2. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

    \[Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  3. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

    Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  4. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]

    \[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  5. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]

    \[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Hour 24 (Double-blind Period)

  6. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]

    \[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  7. Percentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

  8. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  9. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 during the Double-Blind Period are reported. Assessments were performed using the 4- grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  10. Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  11. Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  12. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Hour 24 (Double-blind Period)

  13. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  14. Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 10 (Look Angry). Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  15. Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 5 (Look Less Attractive). Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

07

Results

Posted Feb 18, 2026

Participant flow

Double-Blind Period
Participant flow — Double-Blind Period
MilestonePlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
Started822270000
Completed751990000
Not completed7280000
Withdrew: Lost to follow-up040000
Withdrew: Withdrawal by subject7210000
Withdrew: Withdrawal by subject due to adverse event020000
Withdrew: Other010000
Open-Label Period
Participant flow — Open-Label Period
MilestonePlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
Started002738191
Completed000700189
Not completed002382
Withdrew: Lost to follow-up001011
Withdrew: Withdrawal by subject001351
Withdrew: Withdrawal by subject due to adverse event000020

Outcome measures

PrimaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]

\[Primary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]1.2 (0.0 to 3.6)65.7 (59.5 to 71.9)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 64.5 · 95% CI 57.9 to 71.1Difference: AGN-151586 - Placebo
PrimaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

\[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]0.0 (0.0 to 0.0)67.9 (60.7 to 75.0)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 67.9 · 95% CI 60.7 to 75.0Difference: AGN-151586 - Placebo
PrimaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

\[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]0.0 (0.0 to 0.0)73.6 (66.8 to 80.4)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 73.6 · 95% CI 66.8 to 80.4Difference: AGN-151586 - Placebo
PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

Time frame:
From time of informed consent to end of study; median time on follow-up was 85 days for all groups.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
Any TEAE1948018044
TESAE010000
SecondaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Participant Assessments of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

\[Secondary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Participant Assessments of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]
percentage of participantsPlaceboAGN-151586
Hour 80.0 (0.0 to 0.0)5.3 (2.4 to 8.2)
Hour 120.0 (0.0 to 0.0)18.2 (13.1 to 23.2)
Hour 240.0 (0.0 to 0.0)34.4 (28.2 to 40.6)
Hour 360.0 (0.0 to 0.0)50.2 (43.6 to 56.7)
Hour 480.0 (0.0 to 0.0)55.9 (49.5 to 62.4)
Day 71.2 (0.0 to 3.6)65.7 (59.5 to 71.9)
Day 140.0 (0.0 to 0.0)23.2 (17.7 to 28.8)
Day 210.0 (0.0 to 0.0)1.3 (0.0 to 2.8)
Day 280.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Day 350.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Day 430.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

\[Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]
percentage of participantsPlaceboAGN-151586
Hour 80.0 (0.0 to 0.0)9.3 (5.5 to 13.0)
Hour 120.0 (0.0 to 0.0)24.2 (18.6 to 29.8)
Hour 241.2 (0.0 to 3.6)44.7 (38.2 to 51.1)
Hour 360.0 (0.0 to 0.0)59.0 (52.5 to 65.4)
Hour 480.0 (0.0 to 0.0)65.2 (59.0 to 71.4)
Day 72.4 (0.0 to 5.8)75.5 (69.8 to 81.1)
Day 141.2 (0.0 to 3.6)28.2 (22.3 to 34.1)
Day 210.0 (0.0 to 0.0)2.8 (0.6 to 5.0)
Day 280.0 (0.0 to 0.0)0.5 (0.0 to 1.4)
Day 350.0 (0.0 to 0.0)0.5 (0.0 to 1.4)
Day 430.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]
percentage of participantsPlaceboAGN-151586
Hour 80.0 (0.0 to 0.0)7.5 (4.1 to 11.0)
Hour 120.0 (0.0 to 0.0)21.1 (15.8 to 26.5)
Hour 240.2 (0.0 to 1.6)37.1 (30.8 to 43.4)
Hour 360.0 (0.0 to 0.0)53.1 (46.6 to 59.6)
Hour 480.0 (0.0 to 0.0)58.6 (52.2 to 65.0)
Day 71.2 (0.0 to 3.6)69.4 (63.4 to 75.4)
Day 140.0 (0.0 to 0.0)30.2 (24.1 to 36.2)
Day 210.0 (0.0 to 0.0)4.0 (1.4 to 6.6)
Day 280.0 (0.0 to 0.0)2.6 (0.6 to 4.7)
Day 350.0 (0.0 to 0.0)1.8 (0.1 to 3.5)
Day 430.0 (0.0 to 0.0)0.9 (0.0 to 2.1)
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]

\[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]9.8 (3.3 to 16.2)84.9 (80.1 to 89.6)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 75.1 · 95% CI 67.1 to 83.1Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]

\[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]13.7 (6.2 to 21.3)69.3 (63.3 to 75.3)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 55.6 · 95% CI 45.9 to 65.2Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]

\[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]13.4 (6.0 to 20.8)84.7 (79.9 to 89.5)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 71.3 · 95% CI 62.5 to 80.1Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]7.9 (1.3 to 14.6)61.9 (54.4 to 69.3)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 54.0 · 95% CI 43.9 to 64.0Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]0.3 (0.0 to 2.0)39.8 (32.3 to 47.3)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 39.6 · 95% CI 31.8 to 47.3Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 during the Double-Blind Period are reported. Assessments were performed using the 4- grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]0.0 (0.0 to 0.0)44.7 (37.1 to 52.4)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 44.7 · 95% CI 37.1 to 52.4Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]14.2 (5.6 to 22.9)72.4 (65.5 to 79.3)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 58.2 · 95% CI 47.1 to 69.3Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]10.2 (2.6 to 17.9)78.7 (72.4 to 85.0)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 68.5 · 95% CI 58.6 to 78.4Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]9.9 (2.4 to 17.5)68.5 (61.3 to 75.6)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 58.5 · 95% CI 48.1 to 69.0Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]7.9 (1.3 to 14.6)86.0 (80.6 to 91.4)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 78.1 · 95% CI 69.5 to 86.7Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 10 (Look Angry). Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]7.0 (0.4 to 13.6)55.9 (48.2 to 63.6)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate-difference: 48.9 · 95% CI 38.7 to 59.1Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 5 (Look Less Attractive). Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]8.5 (1.4 to 15.6)48.9 (41.1 to 56.7)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = < 0.0001 · Rate-difference: 40.4 · 95% CI 29.9 to 51.0Difference: AGN-151586 - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent to the end of the study. The median time on follow-up was 85 days for all groups.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/82 (0%)0/82 (0%)5/82 (6.1%)
AGN-1515860/227 (0%)1/227 (0.4%)7/227 (3.1%)
Placebo/None0/2 (0%)0/2 (0%)0/2 (0%)
Placebo/AGN-1515860/73 (0%)0/73 (0%)4/73 (5.5%)
AGN-151586/None0/8 (0%)0/8 (0%)0/8 (0%)
AGN-151586/AGN-1515860/191 (0%)0/191 (0%)2/191 (1%)
Most frequent serious events
Most frequent serious events
EventPlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
CHOLECYSTITISHepatobiliary disorders0/821/2270/20/730/80/191
Most frequent other events
Most frequent other events
EventPlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
HEADACHENervous system disorders5/827/2270/24/730/82/191

Baseline characteristics

Intent to Treat Population: all randomized participants, analyzed according to the treatment groups to which they were randomized

Age, Continuous
Age, Continuous(years)PlaceboAGN-151586Total
Mean43.0 ± 13.0843.2 ± 13.1043.1 ± 13.08
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAGN-151586Total
Female64181245
Male184664
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAGN-151586Total
Hispanic or Latino82634
Not Hispanic or Latino74201275
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAGN-151586Total
American Indian or Alaska Native022
Asian41620
Native Hawaiian or Other Pacific Islander224
Black or African American41418
White68189257
More than one race448
Unknown or Not Reported000
Facial Wrinkle Scale (FWS) at Maximum Frown - Participant
Facial Wrinkle Scale (FWS) at Maximum Frown - Participant(Participants)PlaceboAGN-151586Total
0 = None000
1 = Mild000
2 = Moderate255883
3 = Severe57169226
Facial Wrinkle Scale (FWS) at Maximum Frown - Investigator
Facial Wrinkle Scale (FWS) at Maximum Frown - Investigator(Participants)PlaceboAGN-151586Total
0 = None000
1 = Mild000
2 = Moderate256085
3 = Severe57167224
08

Study locations

17 sites
  • Clear Dermatology & Aesthetics Center /ID# 238990
    Scottsdale, Arizona 85255-4134, United States
  • Steve Yoelin MD Medical Associate Inc /ID# 243197
    Newport Beach, California 92663, United States
  • Marcus Medical Spa /ID# 241703
    Redondo Beach, California 90277, United States
  • DMR Research PLLC /ID# 239061
    Westport, Connecticut 06880, United States
  • Duplicate_Kavali Plastic Surgery and Skin Renewal Center /ID# 244808
    Atlanta, Georgia 30328, United States
  • DelRicht Research /ID# 244890
    Baton Rouge, Louisiana 70809, United States
  • Maryland Dermatology Laser, Skin, & Vein Institute /ID# 239067
    Hunt Valley, Maryland 21030-3216, United States
  • WDC Cosmetic and Research, PLLC /ID# 233935
    Wilmington, North Carolina 28405, United States
  • Clinical Research Center of the Carolinas /ID# 239064
    Charleston, South Carolina 29407, United States
  • Duplicate_Austin Institute for Clinical Research /ID# 238989
    Pflugerville, Texas 78660, United States
  • Kalo Clinical Research /ID# 247279
    West Valley City, Utah 84120-2058, United States
  • SkinDC /ID# 238988
    Arlington, Virginia 22209, United States
  • YVR Aesthetics Training & Study Centre /ID# 241858
    Vancouver, British Columbia V5Z 1H2, Canada
  • Pacific Derm /ID# 239654
    Vancouver, British Columbia V6H 4E1, Canada
  • Dr Melinda Gooderham Medicine Profession /ID# 239657
    Cobourg, Ontario K9A 0Z4, Canada
  • The Centre for Clinical Trials /ID# 245873
    Oakville, Ontario L6J 7W5, Canada
  • Clinique D /ID# 239653
    Laval, Quebec H7N 6L2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Feb 2023, 10 months.

Results were first posted in Feb 2026, 3 years after primary completion. A results delay was requested in Jan 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 21, 2022
StartActual
Mar 8, 2022
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Results delay requested
Jan 8, 2024
Results first posted
Feb 18, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05248880
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Mar 8, 2022
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Results posted
Feb 18, 2026
Last update
Feb 18, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: trenibotulinumtoxinE

Start the discussion